NCT00571675已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Ascenta Therapeutics0 个研究点目标入组 220 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
- 主要终点
- To evaluate and compare the two treatment arms with respect to overall survival (OS)
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.
详细描述
Further Study Details provided by Ascenta.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males age ≥ 18 years with histologically confirmed adenocarcinoma of the prostate, which is now metastatic (e.g. any T, any N, M1a-c) based on bone scan, CT scan, or MRI scan.
- •Progression of disease despite androgen deprivation (androgen ablation or surgical castration) and anti-androgen withdrawal as documented by one or more of the following.
- •Progression of measurable disease per RECIST
- •Bone scan progression, defined as the appearance of ≥ 2 new lesions on bone scan, attributable to prostate cancer
- •Rising PSA, as defined by increasing levels on at least two consecutive assessments, following a prior assessment taken as a reference value, where all of the following are met:
- •The assessments are at least one week apart, with the first assessment at least one week later than the reference value
- •Progressive increase in the two assessments after the reference value, without an intervening decrease between assessments.
- •The last value prior to study entry is ≥ 2 ng/mL
- •Serum testosterone level ≤ 50 ng/dL post orchiectomy or while maintained on continuous or intermittent medical androgen suppression with a LHRH agonist or antagonist.
- •At least 2 weeks since ketoconazole or systemic steroids (any dose); 2 weeks since prior flutamide, megestrol, or aminoglutethimide; and at least 2 weeks since prior bicalutamide or nilutamide
- •Radiation therapy and/or therapy with samarium must have been completed 4 weeks prior to first dose of therapy. Strontium therapy must have been completed at least 12 weeks prior to the first dose of therapy. The patient must have recovered from all treatment-related toxicities.
- •ECOG performance status ≤ 2
- •Able to swallow and retain oral medication
排除标准
- •Received prior chemotherapy (including estramustine phosphate [Estracyt]) for HRPC. Adjuvant chemotherapy (including docetaxel) is allowed provided that progression of disease occurred ≥ 6 months after the completion of adjuvant therapy.
- •Patients must not be receiving concurrent anti-androgen hormonal therapy for HRPC (LHRH directed therapies are acceptable to maintain castrate levels of testosterone).
- •Treatment with monoclonal antibody (e.g., VEGF targeting antibody) or prostate cancer vaccine within 45 days prior to the first dose of study treatment. Acute toxicities from prior therapy must have resolved to Grade ≤
- •Known history of or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis
- •Active secondary malignancy or history of other malignancy within the last 5 years
- •Prior history of radiation therapy to ≥ 30% of the bone marrow
- •Peripheral neuropathy of ≥ Grade 2
- •Patients with malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel are excluded. Subjects with ulcerative colitis, inflammatory bowel disease, or partial or complete small bowel obstruction are also excluded.
- •Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
- •Known active symptomatic fungal, bacterial and/or viral infection including active HIV. Note: screening for viruses is not required.
- •Psychiatric illness/social situations that would limit compliance with the study requirements.
研究组 & 干预措施
1
Experimental
AT-101, prednisone and docetaxel
干预措施: AT-101, prednisone and docetaxel (Drug)
2
Placebo Comparator
Placebo, prednisone and docetaxel
干预措施: placebo, prednisone and docetaxel (Drug)
结局指标
主要结局
To evaluate and compare the two treatment arms with respect to overall survival (OS)
时间窗: 33 months
次要结局
- To evaluate and compare progression-free survival (PFS) in men with chemotherapy-naïve metastatic HRPC treated with AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo.(33 months)
- To determine the toxicities associated with oral AT-101 administered in combination with docetaxel and prednisone.(28 months)
- To evaluate PSA and objective tumor response rate.(28 months)
研究者
相似试验
已完成
2 期
Safety and Immunogenicity of HIL-214 With Routine Pediatric VaccinesGastroenteritisNCT05836012HilleVax329
进行中（未招募）
2 期
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot UlcersDiabetic Foot UlcersNCT06189638Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.90
已完成
2 期
ALPN-101 (Acazicolcept) in Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT04835441Alpine Immune Sciences Inc, A Subsidiary of Vertex76
终止
2 期
A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe AsthmaAsthmaNCT05155020Akeso1
招募中
2 期
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesHigher-risk Myelodysplastic SyndromesNCT06196203Akeso90